FGFR-3 mediated neoplasm has been reported in bladder cancer, multiple myeloma, cervical and prostate cancer [101-105], and FGFR-4 mutation has been reported in cases of bladder rhabdomyosarcoma and breast cancer [106-108]. This evidence concerns the gene FGFR3 and plasma cell myeloma.